GlassScriptPhysician profile
Deborah R Berry
NPI 1457880049
$2,574.29
in general payments reported to CMS, 2019-2025
25 companies · $465 in 2025
The $465 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $462 · 2023: $790 · 2024: $857 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.26 |
| Education | $261.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $560.11 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $335.93 | 2023-2025 | |
| Celgene Corporation | $335.40 | 2023-2025 | Pomalyst, Reblozyl, Opdivo |
| Abbvie INC. | $188.93 | 2024 | |
| Seagen INC. | $184.98 | 2022 | |
| Amgen INC. | $182.64 | 2025 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $84.42 | 2022-2025 | Keytruda, Welireg |
| Gilead Sciences, INC. | $82.99 | 2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $76.18 | 2022-2023 | Calquence, Tagrisso, Imfinzi |
| Array Biopharma INC | $63.92 | 2024 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $55.39 | 2023-2024 | Krazati |
| Pfizer INC. | $53.62 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $52.92 | 2023-2024 | |
| Incyte Corporation | $46.27 | 2024 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $40.74 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $35.66 | 2023 | Fotivda |
| Rigel Pharmaceuticals, INC. | $27.81 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $26.38 | 2023 | Epkinly |
| Eisai INC. | $23.53 | 2023 | |
| Pharmaessentia USA Corporation | $23.34 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $22.71 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $20.20 | 2024 | Opdivo |
| Geron Corporation | $19.77 | 2025 | Rytelo |
| Morphosys, US INC. | $15.55 | 2024 | Monjuvi |
| Sobi, INC | $14.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.